EUMETSAT Moodle

Creative Bioarray provides high quality drug-drug interaction services, including identification of drug metabolizing enzymes, CYP and UGT inhibition assays, and inhibition studies towards less common metabolizing enzymes, such as MAO, FMO, NAT, AOX, and CES.

Metabolism-mediated drug-drug interactions (DDI) refer to the interference of simultaneously administered drugs with each other's ADME (absorption, distribution, metabolism, and elimination) process by inducing or inhibiting the activities of drug metabolizing enzymes and/or drug transporters. Concomitant medications may result in an abrupt alteration in metabolism or transport that can lead to an unwanted augmentation or decrease in the blood level of a drug administered to a patient, changing the known safety and efficacy of a drug and leading to severe side effects.  Thus evaluation of new drug candidates for DDI is recommended by the US Food and Drug Administration (FDA).